Performance characteristics of qualified cell lines for isolation and propagation of influenza viruses for vaccine manufacturing

Vaccine

Volumn 32, Issue 48, 2014, Pages 6583-6590

  Donis, Ruben O ^a   Ziegler, Thedi ^a,n   Chen, i Mei ^b   Davis, C Todd ^b   Foust, Angie ^b   Hossain, M Jaber ^b   Johnson, Adam ^b   Klimov, Alexander ^b   Loughlin, Rosette ^b   Xu, Xiyan ^b   Tsai, Theodore ^c   Blayer, Simone ^d,l   Trusheim, Heidi ^d   Colegate, Tony ^e   Fox, John ^e   Taylor, Beverly ^e   Hussain, Althaf ^f,m   Barr, Ian ^g   Baas, Chantal ^g   Louwerens, Jaap ^h   Geuns, Ed ^h   Lee, Min Shi ⁱ   Venhuizen, Lodewijk ^j   Neumeier, Elisabeth ^k   more..

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (United States)

^c Global Medical Affairs   (Germany)

^d Novartis Vaccines and Diagnostics   (United Kingdom)

^e MEDIMMUNE   (United States)

^f WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^g Chemical Design and Synthesis Unit   (Netherlands)

^h NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

ⁱ CRUCELL HOLLAND BV   (Netherlands)

^j Global Industrial Operations   (Germany)

^k NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^l Astellas Pharma Europe Leiderdorp   (Netherlands)

^m NATIONAL INSTITUTES OF HEALTH   (United States)

ⁿ UNIVERSITY OF TURKU   (Finland)

more..

Author keywords

Antigenic stability; Genetic stability; Influenza vaccines; MDCK; Vaccine certified cell lines; VERO; Virus isolation; Virus purification

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIGEN; VIRUS SIALIDASE;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIGENICITY; ARTICLE; FEASIBILITY STUDY; HEMAGGLUTINATION INHIBITION; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INOCULATION; MDCK CELL LINE; NONHUMAN; PROTEIN STABILITY; VACCINE PRODUCTION; VERO CELL LINE; VIROGENESIS; VIRUS ISOLATION; ANIMAL; ANTIGENIC VARIATION; CHLOROCEBUS AETHIOPS; DOG; FERRET; GROWTH, DEVELOPMENT AND AGING; HEMAGGLUTINATION INHIBITION TEST; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); ORTHOMYXOVIRIDAE; VIROLOGY; VIRUS CULTURE;

ANIMALS; ANTIGENIC VARIATION; ANTIGENS, VIRAL; CERCOPITHECUS AETHIOPS; DOGS; FERRETS; HEMAGGLUTINATION INHIBITION TESTS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; MADIN DARBY CANINE KIDNEY CELLS; ORTHOMYXOVIRIDAE; VERO CELLS; VIRUS CULTIVATION;

EID: 84908568634     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.045     Document Type: Article

References (47)

1. Abelin A., Colegate T., Gardner S., Hehme N., Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011, 29:1135-1138.
2. Doroshenko A., Halperin S.A. Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines). Expert Rev Vaccines 2009, 8:679-688.
3. Barrett P.N., Portsmouth D., Ehrlich H.J. Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development. Expert Rev Vaccines 2013, 12:395-413.
4. Minor P.D., Engelhardt O.G., Wood J.M., Robertson J.S., Blayer S., Colegate T., et al. Current challenges in implementing cell-derived influenza vaccines: implications for production and regulation, July 2007, NIBSC, Potters Bar, UK. Vaccine 2009, 27:2907-2913.
5. Ampofo W.K., Baylor N., Cobey S., Cox N.J., Daves S., Edwards S., et al. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. Influenza Other Respir Viruses 2012, 6:142-152. e1-5.
6. Minor P.D. Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production. Clin Infect Dis 2010, 50:560-565.
7. Stohr K., Bucher D., Colgate T., Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol 2012, 865:147-162.
8. Stohr K. Influenza-WHO cares. Lancet Infect Dis 2002, 2:517.
9. Russell C.A., Jones T.C., Barr I.G., Cox N.J., Garten R.J., Gregory V., et al. Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 2008, 26(Suppl. 4):D31-D34.
10. CBER/FDA Guidance for industry on characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications 2010, Food and Drug Administration, Center for Biologics Evaluation and Research, Washington, DC. Services USDoHaH (Ed.).
11. CBER/FDA Guidance for industry on content and format of chemistry, manufacturing and controls information and establishment description information for a vaccine or related product 1999, Food and Drug Administration, Center for Biologics Evaluation and Research, Washington, DC. Services USDoHaH (Ed.).
12. Liu J., Mani S., Schwartz R., Richman L., Tabor D.E. Cloning and assessment of tumorigenicity and oncogenicity of a Madin-Darby canine kidney (MDCK) cell line for influenza vaccine production. Vaccine 2010, 28:1285-1293.
13. Palache A.M., Brands R., van Scharrenburg G.J. Immunogenicity and reactogenicity of influenza subunit vaccines produced in MDCK cells or fertilized chicken eggs. J Infect Dis 1997, 176(Suppl. 1):S20-S23.
14. Liu J., Shi X., Schwartz R., Kemble G. Use of MDCK cells for production of live attenuated influenza vaccine. Vaccine 2009, 27:6460-6463.
15. Medema J.K., Meijer J., Kersten A.J., Horton R. Safety assessment of Madin Darby canine kidney cells as vaccine substrate. Dev Biol (Basel) 2006, 123:243-250. discussion 65-6.
16. Hussain A.I., Cordeiro M., Sevilla E., Liu J. Comparison of egg and high yielding MDCK cell-derived live attenuated influenza virus for commercial production of trivalent influenza vaccine: in vitro cell susceptibility and influenza virus replication kinetics in permissive and semi-permissive cells. Vaccine 2010, 28:3848-3855.
17. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 1998, 16:960-968.
18. Barrett P.N., Berezuk G., Fritsch S., Aichinger G., Hart M.K., El-Amin W., et al. Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2011, 377:751-759.
19. Ehrlich H.J., Berezuk G., Fritsch S., Aichinger G., Singer J., Portsmouth D., et al. Clinical development of a Vero cell culture-derived seasonal influenza vaccine. Vaccine 2012, 30:4377-4386.
20. Ehrlich H.J., Singer J., Berezuk G., Fritsch S., Aichinger G., Hart M.K., et al. A cell culture-derived influenza vaccine provides consistent protection against infection and reduces the duration and severity of disease in infected individuals. Clin Infect Dis. 2012, 54:946-954.
21. Fischer S., Charara N., Gerber A., Wolfel J., Schiedner G., Voedisch B., et al. Transient recombinant protein expression in a human amniocyte cell line: the CAP-T(R) cell system. Biotechnol Bioeng 2012, 109:2250-2261.
22. Pau M.G., Ophorst C., Koldijk M.H., Schouten G., Mehtali M., Uytdehaag F. The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines. Vaccine 2001, 19:2716-2721.
23. Cox R.J., Madhun A.S., Hauge S., Sjursen H., Major D., Kuhne M., et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009, 27:1889-1897.
24. WHO WHO guidelines on nonclinical evaluation of vaccines. WHO technical report series no 927, annex 1 2005, WHO, Geneva, Switzerland.
25. European Medicines Agency Committee for medicinal products for human use VWPa BWPV, BWP). Guideline on influenza vaccines-quality module (draft for comment) 2013, Vaccine Working Party and Biologics Working Party (VWP, BWP).
26. Katz J.M., Wang M., Webster R.G. Direct sequencing of the HA gene of influenza (H3N2) virus in original clinical samples reveals sequence identity with mammalian cell-grown virus. J Virol 1990, 64:1808-1811.
27. Meyer W.J., Wood J.M., Major D., Robertson J.S., Webster R.G., Katz J.M. Influence of host cell-mediated variation on the international surveillance of influenza A(H3N2) viruses. Virology 1993, 196:130-137.
28. Robertson J.S., Nicolson C., Major D., Robertson E.W., Wood J.M. The role of amniotic passage in the egg-adaptation of human influenza virus is revealed by haemagglutinin sequence analyses. J Gen Virol 1993, 74(Pt 10):2047-2051.
29. Robertson J.S., Naeve C.W., Webster R.G., Bootman J.S., Newman R., Schild G.C. Alterations in the hemagglutinin associated with adaptation of influenza B virus to growth in eggs. Virology 1985, 143:166-174.
30. Robertson J.S., Bootman J.S., Newman R., Oxford J.S., Daniels R.S., Webster R.G., et al. Structural changes in the haemagglutinin which accompany egg adaptation of an influenza A(H1N1) virus. Virology 1987, 160:31-37.
31. Kishida N., Fujisaki S., Yokoyama M., Sato H., Saito R., Ikematsu H., et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of post vaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 2012, 19:897-908.
32. EMA Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture 2011, Committee for Human Medicinal Products (CHMP), European Medicines Agency, London, UK.
33. Gregersen J.P. A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine. Vaccine 2008, 26:3332-3340.
34. Onions D., Egan W., Jarrett R., Novicki D., Gregersen J.P. Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine. Biologicals: J Int Assoc Biol Stand 2010, 38:544-551.
35. Zhou B., Donnelly M., Scholes D., St George K., Hatta M., Kawaoka Y., et al. Single-reaction genomic amplification accelerates sequencing and vaccine production for classical and Swine origin human influenza a viruses. J Virol 2009, 83:10309-10313.
36. WHO Manual for the laboratory diagnosis and virological surveillance of influenza 2011, WHO Press, Geneva.
37. Lane R.D., Federman D., Flora J.L., Beck B.L. Computer-assisted determination of protein concentrations from dye-binding and bicinchoninic acid protein assays performed in microtiter plates. J Immunol Methods 1986, 92:261-270.
38. Donis R., Blayer S., Colegate A., Ziegler T., Barr I., Bucher D., et al. Evaluation of qualified cell lines for isolation of influenza candidate vaccine viruses: from clinical specimen to high yield reassortant. 4th ESWI influenza conference 2011, ESWI, Malta. ESWI (Ed.).
39. Gambaryan A.S., Robertson J.S., Matrosovich M.N. Effects of egg-adaptation on the receptor-binding properties of human influenza A and B viruses. Virology 1999, 258:232-239.
40. Hardy C.T., Young S.A., Webster R.G., Naeve C.W., Owens R.J. Egg fluids and cells of the chorioallantoic membrane of embryonated chicken eggs can select different variants of influenza A(H3N2) viruses. Virology 1995, 211:302-306.
41. Ito T., Suzuki Y., Takada A., Kawamoto A., Otsuki K., Masuda H., et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol 1997, 71:3357-3362.
42. Katz J.M., Webster R.G. Amino acid sequence identity between the HA1 of influenza A(H3N2) viruses grown in mammalian and primary chick kidney cells. J Gen Virol 1992, 73(Pt 5):1159-1165.
43. Rogers G.N., Daniels R.S., Skehel J.J., Wiley D.C., Wang X.F., Higa H.H., et al. Host-mediated selection of influenza virus receptor variants, sialic acid-α2,6Gal-specific clones of A/duck/Ukraine/1/63 revert to sialic acid-α2,3Gal-specific wild type in ovo. J Biol Chem 1985, 260:7362-7367.
44. Widjaja L., Ilyushina N., Webster R.G., Webby R.J. Molecular changes associated with adaptation of human influenza A virus in embryonated chicken eggs. Virology 2006, 350:137-145.
45. Reina J., Fernandez-Baca V., Blanco I., Munar M. Comparison of Madin-Darby canine kidney cells (MDCK) with a green monkey continuous cell line (Vero) and human lung embryonated cells (MRC-5) in the isolation of influenza A virus from nasopharyngeal aspirates by shell vial culture. J Clin Microbiol 1997, 35:1900-1901.
46. Romanova J., Katinger D., Ferko B., Voglauer R., Mochalova L., Bovin N., et al. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology 2003, 307:90-97.
47. Lu B., Zhou H., Ye D., Kemble G., Jin H. Improvement of influenza A/Fujian/411/02 (H3N2) virus growth in embryonated chicken eggs by balancing the hemagglutinin and neuraminidase activities, using reverse genetics. J Virol 2005, 79:6763-6771.